Staar Surgical (STAA) Gains from Sales and Divestitures (2021 - 2026)

Staar Surgical has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $453000.0 in Q2 2026.

• For the quarter ending Q2 2026, Gains from Sales and Divestitures rose 103.14% year-over-year to $453000.0; the trailing twelve-month figure through Apr 2026 stood at $453000.0 (up 103.14% YoY), and the FY2026 full-year result was $321000.0, up 3110.0% from the prior year.
• Gains from Sales and Divestitures for Q2 2026 stood at $453000.0, up from $321000.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $453000.0 in Q2 2026, with the low at $4000.0 in Q3 2023.
• Historically, Gains from Sales and Divestitures has averaged $94470.6 across 5 years, with a median of $45000.0 in 2022.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures plunged 92.98% — and 2026, when it jumped 3110.0%.
• Staar Surgical's Gains from Sales and Divestitures stood at $5000.0 in 2022, then surged by 600.0% to $35000.0 in 2023, then sank by 71.43% to $10000.0 in 2024, then surged by 100.0% to $20000.0 in 2025, then soared by 2165.0% to $453000.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $453000.0 (Q2 2026), $321000.0 (Q1 2026), and $20000.0 (Q3 2025), per Business Quant data.